High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study
Background: We examined whether high-sensitivity CRP (hsCRP) reflected the inflammatory disease status evaluated by clinical and ultrasound (US) parameters in RA patients receiving IL-6 receptor antibodies (anti-IL-6R) or JAK inhibitors (JAKi). Methods: We conducted a cross-sectional study of patien...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/12/1/182 |
| _version_ | 1797494627536732160 |
|---|---|
| author | Beatriz Frade-Sosa Andrés Ponce Virginia Ruiz-Esquide Maria Jesús García-Yébenes Rosa Morlá Nuria Sapena Julio Ramirez Ana Belen Azuaga Juan Camilo Sarmiento Juan D. Cañete Jose A. Gomez-Puerta Raimon Sanmarti |
| author_facet | Beatriz Frade-Sosa Andrés Ponce Virginia Ruiz-Esquide Maria Jesús García-Yébenes Rosa Morlá Nuria Sapena Julio Ramirez Ana Belen Azuaga Juan Camilo Sarmiento Juan D. Cañete Jose A. Gomez-Puerta Raimon Sanmarti |
| author_sort | Beatriz Frade-Sosa |
| collection | DOAJ |
| description | Background: We examined whether high-sensitivity CRP (hsCRP) reflected the inflammatory disease status evaluated by clinical and ultrasound (US) parameters in RA patients receiving IL-6 receptor antibodies (anti-IL-6R) or JAK inhibitors (JAKi). Methods: We conducted a cross-sectional study of patients with established RA receiving anti-IL-6R (tocilizumab, sarilumab) or JAKi (tofacitinib, baricitinib). Serum hsCRP and US synovitis in both hands were measured. Associations between hsCRP and clinical inflammatory activity were evaluated using composite activity indices. The association between hsCRP and US synovitis was analyzed. Results: 63 (92% female) patients (42 anti- IL-6R and 21 JAKi) were included, and the median disease duration was 14.4 (0.2–37.5) years. Most patients were in remission or had low levels of disease. Overall hsCRP values were very low, and significantly lower in anti-IL-6R patients (median 0.04 mg/dL vs. 0.16 mg/dL). Anti-IL-6R (82.4%) patients and 48% of JAKi patients had very low hsCRP levels (≤0.1 mg/dL) (<i>p</i> = 0.002). In the anti-IL-6R group, hsCRP did not correlate with the composite activity index or US synovitis. In the JAKi group, hsCRP moderately correlated with US parameters (r = 0.5) but not clinical disease activity, and hsCRP levels were higher in patients with US synovitis (0.02 vs. 0.42 mg/dL) (<i>p</i> = 0.001). Conclusion: In anti-IL-6R RA-treated patients, hsCRP does not reflect the inflammatory disease state, but in those treated with JAKi, hsCRP was associated with US synovitis. |
| first_indexed | 2024-03-10T01:37:03Z |
| format | Article |
| id | doaj.art-02369a30c17c4105a6e0126965925d97 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T01:37:03Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-02369a30c17c4105a6e0126965925d972023-11-23T13:29:43ZengMDPI AGDiagnostics2075-44182022-01-0112118210.3390/diagnostics12010182High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic StudyBeatriz Frade-Sosa0Andrés Ponce1Virginia Ruiz-Esquide2Maria Jesús García-Yébenes3Rosa Morlá4Nuria Sapena5Julio Ramirez6Ana Belen Azuaga7Juan Camilo Sarmiento8Juan D. Cañete9Jose A. Gomez-Puerta10Raimon Sanmarti11Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, SpainDepartment of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, SpainDepartment of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, SpainInstituto de Salud Musculoesquelética, 28045 Madrid, SpainDepartment of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, SpainDepartment of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, SpainDepartment of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, SpainDepartment of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, SpainDepartment of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, SpainDepartment of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, SpainDepartment of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, SpainDepartment of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, SpainBackground: We examined whether high-sensitivity CRP (hsCRP) reflected the inflammatory disease status evaluated by clinical and ultrasound (US) parameters in RA patients receiving IL-6 receptor antibodies (anti-IL-6R) or JAK inhibitors (JAKi). Methods: We conducted a cross-sectional study of patients with established RA receiving anti-IL-6R (tocilizumab, sarilumab) or JAKi (tofacitinib, baricitinib). Serum hsCRP and US synovitis in both hands were measured. Associations between hsCRP and clinical inflammatory activity were evaluated using composite activity indices. The association between hsCRP and US synovitis was analyzed. Results: 63 (92% female) patients (42 anti- IL-6R and 21 JAKi) were included, and the median disease duration was 14.4 (0.2–37.5) years. Most patients were in remission or had low levels of disease. Overall hsCRP values were very low, and significantly lower in anti-IL-6R patients (median 0.04 mg/dL vs. 0.16 mg/dL). Anti-IL-6R (82.4%) patients and 48% of JAKi patients had very low hsCRP levels (≤0.1 mg/dL) (<i>p</i> = 0.002). In the anti-IL-6R group, hsCRP did not correlate with the composite activity index or US synovitis. In the JAKi group, hsCRP moderately correlated with US parameters (r = 0.5) but not clinical disease activity, and hsCRP levels were higher in patients with US synovitis (0.02 vs. 0.42 mg/dL) (<i>p</i> = 0.001). Conclusion: In anti-IL-6R RA-treated patients, hsCRP does not reflect the inflammatory disease state, but in those treated with JAKi, hsCRP was associated with US synovitis.https://www.mdpi.com/2075-4418/12/1/182IL-6 inhibitorJAK inhibitorrheumatoid arthritisultrasound synovitishigh-sensitivity C-reactive protein |
| spellingShingle | Beatriz Frade-Sosa Andrés Ponce Virginia Ruiz-Esquide Maria Jesús García-Yébenes Rosa Morlá Nuria Sapena Julio Ramirez Ana Belen Azuaga Juan Camilo Sarmiento Juan D. Cañete Jose A. Gomez-Puerta Raimon Sanmarti High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study Diagnostics IL-6 inhibitor JAK inhibitor rheumatoid arthritis ultrasound synovitis high-sensitivity C-reactive protein |
| title | High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study |
| title_full | High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study |
| title_fullStr | High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study |
| title_full_unstemmed | High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study |
| title_short | High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study |
| title_sort | high sensitivity c reactive protein in patients with rheumatoid arthritis treated with antibodies against il 6 or jak inhibitors a clinical and ultrasonographic study |
| topic | IL-6 inhibitor JAK inhibitor rheumatoid arthritis ultrasound synovitis high-sensitivity C-reactive protein |
| url | https://www.mdpi.com/2075-4418/12/1/182 |
| work_keys_str_mv | AT beatrizfradesosa highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT andresponce highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT virginiaruizesquide highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT mariajesusgarciayebenes highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT rosamorla highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT nuriasapena highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT julioramirez highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT anabelenazuaga highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT juancamilosarmiento highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT juandcanete highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT joseagomezpuerta highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT raimonsanmarti highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy |